Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. arket Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing awareness by educating people living with glioblastoma multiforme through various initiatives undertaken by governments and non-government bodies across the globe is expected to drive market growth.
4.1.2. Restraints:
4.1.2.1. The high cost associated with treating the glioblastoma multiforme is a major factor that hampers the market growth.
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces
5.2. Supply Chain
5.3. Pricing Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
7.1.2. Market Attractiveness Index, By Treatment Type
7.2. Chemotherapy*
7.2.1.1. Temozolomide
7.2.1.2. Introduction
7.2.1.3. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.2.1.4. Bevacizumab
7.2.1.5. Carmustine
7.2.1.6. Others
7.3. Immunotherapy
7.4. Electric-field therapy
7.5. Others
8. By Type of Molecule
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule
8.1.2. Market Attractiveness Index, By Type of Molecule
8.2. Small Molecules*
8.2.1.1. Introduction
8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Biologics
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral*
9.2.1.1. Introduction
9.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Parenteral
10. By End user
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.1.2. Market Attractiveness Index, By End user
10.2. Hospitals*
10.2.1.1. Introduction
10.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Clinics
10.4. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule
11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule
11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecules
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecules
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecules
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Genentech*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. Amgen
13.3. Merck & Co., Inc
13.4. Teva Pharmaceutical Industries, Ltd.
13.5. Arbor Pharmaceuticals LLC
13.6. Sun Pharmaceutical Industries, Ltd.
13.7. F. Hoffman-La Roche
13.8. Novartis AG
13.9. Pfizer
LIST NOT EXHAUSTIVE
14. Global Glioblastoma Treatment Market– DataM
14.1. Appendix
14.2. About Us and Applications
14.3. Contact Us